Pre-treatment testosterone levels: significance in androgen deprivation therapy.

作者: David Hickey , Barbara Todd , Mark S. Soloway

DOI: 10.1016/S0022-5347(17)45200-1

关键词:

摘要: From June 1982 to February 1985, 53 patients with stage D2 carcinoma of the prostate confirmed by tissue biopsy, elevated prostatic acid phosphatase and a positive bone scan were initiated on androgen deprivation therapy. Before commencement treatment all underwent determination serum testosterone levels at 8 a.m. Of 23 received 200 mcg. buserelin per day, 17 1 mg. diethylstilbestrol 3 times daily, 6 40 megestrol acetate 4 2 leuprolide day 5 bilateral orchiectomy. Evaluation best response in each patient revealed (6 cent) complete (32 partial responses, while 22 (41 remained stable 11 (21 had progression. Pre-treatment ranged from 150 879 ng. dl. The mean level having was 524 +/- 18.04 progression group 279.4 110.1 This difference not statistically significant owing large standard deviation group. However, 15 who pre-treatment more than 500 only (7 None whose less objective tumor regression. Our study suggests that may predict probability satisfactory

参考文章(11)
WILLIAM W. SCOTT, MANI MENON, PATRICK C. WALSH, Hormonal Therapy of Prostatic Cancer Cancer. ,vol. 45, pp. 1929- 1936 ,(1980) , 10.1002/CNCR.1980.45.S7.1929
D. W. Wilson, M. E. Harper, G. Richards, C. G. Pierrepoint, K. Griffiths, H. M. Jensen, R. M. Ikeda, W. B. Peeling, A prognostic index for the clinical management of patients with advanced prostatic cancer: A british prostate study group investigation The Prostate. ,vol. 7, pp. 131- 141 ,(1985) , 10.1002/PROS.2990070203
H. Adlercreutz, S. Rannikko, Anna-Liisa Kairento, Sirkka-Liisa Karonen, Hormonal pattern in prostatic cancer European Journal of Endocrinology. ,vol. 98, pp. 634- 640 ,(1981) , 10.1530/ACTA.0.0980634
CHARLES HUGGINS, STUDIES ON PROSTATIC CANCER Archives of Surgery. ,vol. 43, pp. 209- 223 ,(1941) , 10.1001/ARCHSURG.1941.01210140043004
M. R. G. Robinson, B. S. Thomas, Effect of Hormonal Therapy on Plasma Testosterone Levels in Prostatic Carcinoma BMJ. ,vol. 4, pp. 391- 394 ,(1971) , 10.1136/BMJ.4.5784.391
M.E. Harper, C.G. Pierrepoint, K. Griffiths, Carcinoma of the prostate: Relationship of pretreatment hormone levels to survival European Journal of Cancer and Clinical Oncology. ,vol. 20, pp. 477- 482 ,(1984) , 10.1016/0277-5379(84)90232-3
John T. Grayhack, James M. Kozlowski, Endocrine Therapy in the Management of Advanced Prostatic Cancer - The Case for Early Initiation of Treatment Urologic Clinics of North America. ,vol. 7, pp. 639- 643 ,(1980) , 10.1016/S0094-0143(21)00152-X
Hugh H. Young, John R. Kent, Plasma Testosterone Levels in Patients with Prostatic Carcinoma Before and after Treatment Journal of Urology. ,vol. 99, pp. 788- 792 ,(1968) , 10.1016/S0022-5347(17)62795-2